Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A combination of retinal morphology and visual electrophysiology testing increases diagnostic yield in Parkinson's disease.

Miri S, Glazman S, Mylin L, Bodis-Wollner I.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S134-7. doi: 10.1016/j.parkreldis.2015.09.015. Epub 2015 Sep 5.

PMID:
26414119
2.

Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.

Watson AM, Mylin LM, Thompson MM, Schell TD.

J Immunol. 2012 Dec 15;189(12):5549-60. doi: 10.4049/jimmunol.1102221. Epub 2012 Nov 21.

3.

CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, Tevethia MJ, Tevethia SS, Schell TD.

J Immunol. 2008 Sep 15;181(6):4406-17.

4.

Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS.

Virology. 2007 Jul 20;364(1):155-68. Epub 2007 Mar 21.

5.

Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.

Otahal P, Hutchinson SC, Mylin LM, Tevethia MJ, Tevethia SS, Schell TD.

J Immunol. 2005 Jul 15;175(2):700-12.

6.

In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.

Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS.

J Immunol. 2003 Jul 15;171(2):697-707.

7.
8.

Topographical analysis of the onset VEP in the detection of paracentral visual field defects.

Sartucci F, Tagliati M, Mylin LH, Bodis-Wollner I.

Clin Electroencephalogr. 2002 Apr;33(2):62-9.

PMID:
12025733
9.

Role of CTL host responses and their implication for tumorigenicity testing and the use of tumour cells as vaccine substrate.

Tevethia S, Beachy T, Schell T, Lippolis J, Newmaster R, Mylin L, Tevethia MJ.

Dev Biol (Basel). 2001;106:109-21; discussion 143-60.

PMID:
11761225
11.

Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Schell TD, Mylin LM, Georgoff I, Teresky AK, Levine AJ, Tevethia SS.

J Virol. 1999 Jul;73(7):5981-93.

13.
14.

A molecular basis for how a single TCR interfaces multiple ligands.

Boesteanu A, Brehm M, Mylin LM, Christianson GJ, Tevethia SS, Roopenian DC, Joyce S.

J Immunol. 1998 Nov 1;161(9):4719-27.

15.

Cytotoxic T lymphocyte recognition sequences as markers for distinguishing among tumour antigens encoded by SV40, BKV and JCV.

Tevethia SS, Mylin L, Newmaster R, Epler M, Lednicky JA, Butel JS, Tevethia MJ.

Dev Biol Stand. 1998;94:329-39.

PMID:
9776254
16.

Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection.

Newmaster RS, Mylin LM, Fu TM, Tevethia SS.

Virology. 1998 May 10;244(2):427-41.

17.
19.

Inducible expression cassettes in yeast: GAL4.

Mylin LM, Hopper JE.

Methods Mol Biol. 1997;62:131-48. No abstract available.

PMID:
9108518
20.

Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

Mylin LM, Bonneau RH, Lippolis JD, Tevethia SS.

J Virol. 1995 Nov;69(11):6665-77.

22.

Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen.

Mylin LM, Deckhut AM, Bonneau RH, Kierstead TD, Tevethia MJ, Simmons DT, Tevethi SS.

Virology. 1995 Apr 1;208(1):159-72.

PMID:
11831696
23.

Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease.

Bodis-Wollner I, Borod JC, Cicero B, Haywood CS, Raskin S, Mylin L, Sliwinski M, Falk A, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1995;9(2-3):197-209.

PMID:
8527004
24.

SIP1 is a catabolite repression-specific negative regulator of GAL gene expression.

Mylin LM, Bushman VL, Long RM, Yu X, Lebo CM, Blank TE, Hopper JE.

Genetics. 1994 Jul;137(3):689-700.

25.

The effect of levo-acetyl-carnitine on visual cognitive evoked potentials in the behaving monkey.

Antal A, Bodis-Wollner I, Ghilardi MF, Glover A, Mylin L, Toldi J.

Electroencephalogr Clin Neurophysiol. 1993 Apr;86(4):268-74.

PMID:
7682930
26.

A short latency cortical component of the foveal VEP is revealed by hemifield stimulation.

Bodis-Wollner I, Brannan JR, Nicoll J, Frkovic S, Mylin LH.

Electroencephalogr Clin Neurophysiol. 1992 May-Jun;84(3):201-8.

PMID:
1375879
27.

Sequence conservation in the Saccharomyces and Kluveromyces GAL11 transcription activators suggests functional domains.

Mylin LM, Gerardot CJ, Hopper JE, Dickson RC.

Nucleic Acids Res. 1991 Oct 11;19(19):5345-50.

28.

GAL11 (SPT13), a transcriptional regulator of diverse yeast genes, affects the phosphorylation state of GAL4, a highly specific transcriptional activator.

Long RM, Mylin LM, Hopper JE.

Mol Cell Biol. 1991 Apr;11(4):2311-4. Erratum in: Mol Cell Biol 1991 Jul;11(7):3821.

29.

Visual 'cognitive' evoked potentials in the behaving monkey.

Glover A, Ghilardi MF, Bodis-Wollner I, Onofrj M, Mylin LH.

Electroencephalogr Clin Neurophysiol. 1991 Jan-Feb;80(1):65-72.

PMID:
1703952
30.

N70 and P100 can be independently affected in multiple sclerosis.

Ghilardi MF, Sartucci F, Brannan JR, Onofrj MC, Bodis-Wollner I, Mylin L, Stroch R.

Electroencephalogr Clin Neurophysiol. 1991 Jan-Feb;80(1):1-7.

PMID:
1703943
31.

Phosphorylated forms of GAL4 are correlated with ability to activate transcription.

Mylin LM, Johnston M, Hopper JE.

Mol Cell Biol. 1990 Sep;10(9):4623-9.

32.

Regulated GAL4 expression cassette providing controllable and high-level output from high-copy galactose promoters in yeast.

Mylin LM, Hofmann KJ, Schultz LD, Hopper JE.

Methods Enzymol. 1990;185:297-308. No abstract available.

PMID:
2199783
33.

The auditory P 300 correlates with specific cognitive deficits in Parkinson's disease.

Pang S, Borod JC, Hernandez A, Bodis-Wollner I, Raskin S, Mylin L, Coscia L, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1990;2(4):249-64.

PMID:
2078307
34.

Regulated phosphorylation and dephosphorylation of GAL4, a transcriptional activator.

Mylin LM, Bhat JP, Hopper JE.

Genes Dev. 1989 Aug;3(8):1157-65.

35.

Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity.

Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M.

Brain. 1987 Dec;110 ( Pt 6):1675-98.

PMID:
3427405
36.

Delayed visual evoked potentials are independent of pattern orientation in macular disease.

Bodis-Wollner I, Feldman RG, Guillory SL, Mylin L.

Electroencephalogr Clin Neurophysiol. 1987 May;68(3):172-9.

PMID:
2436876
37.
38.

Plasticity of monocular and binocular vision following cerebral blindness: evoked potential evidence.

Bodis-Wollner I, Mylin L.

Electroencephalogr Clin Neurophysiol. 1987 Jan;68(1):70-4.

PMID:
2431893
39.

Effects of halothane on transport of 5-hydroxytryptamine by platelet membranes.

Watkins CA, Mylin LM, Rannels DE.

Biochem J. 1986 Apr 1;235(1):33-8.

40.

Temporal frequency-dependent VEP changes in Parkinson's disease.

Marx M, Bodis-Wollner I, Bobak P, Harnois C, Mylin L, Yahr M.

Vision Res. 1986;26(1):185-93.

PMID:
3716211
41.

Nonmotor functions of the basal ganglia.

Bodis-Wollner I, Yahr MD, Mylin LH.

Adv Neurol. 1984;40:289-98.

PMID:
6695605
42.

Flicker threshold and pattern VEP latency in ocular hypertension and glaucoma.

Atkin A, Bodis-Wollner I, Podos SM, Wolkstein M, Mylin L, Nitzberg S.

Invest Ophthalmol Vis Sci. 1983 Nov;24(11):1524-8.

PMID:
6642932
43.

Pattern electroretinograms and visual-evoked potentials in glaucoma and multiple sclerosis.

Bobak P, Bodis-Wollner I, Harnois C, Maffei L, Mylin L, Podos S, Thornton J.

Am J Ophthalmol. 1983 Jul;96(1):72-83.

PMID:
6869481
44.

Species-dependent variations in erythrocyte membrane skeletal proteins.

Whitfield CF, Mylin LM, Goodman SR.

Blood. 1983 Mar;61(3):500-6.

PMID:
6824785
45.

On the possible role of temporal delays of afferent processing in Parkinson's disease.

Bodis-Wollner I, Harnois C, Bobak P, Mylin L.

J Neural Transm Suppl. 1983;19:243-52.

PMID:
6321648
46.

Dopaminergic deficiency and delayed visual evoked potentials in humans.

Bodis-Wollner I, Yahr MD, Mylin L, Thornton J.

Ann Neurol. 1982 May;11(5):478-83.

PMID:
6125124
47.

Visual evoked potential diagnosis of field defects in patients with chiasmatic and retrochiasmatic lesions.

Onofrj M, Bodis-Wollner I, Mylin L.

J Neurol Neurosurg Psychiatry. 1982 Apr;45(4):294-302.

48.

The effect of stimulus orientation on the visual evoked potential in multiple sclerosis.

Camisa J, Mylin LH, Bodis-Wollner I.

Ann Neurol. 1981 Dec;10(6):532-9.

PMID:
7325602
49.

Binocular stimulation reveals cortical components of the human visual evoked potential.

Bodis-Wollner I, Barris MC, Mylin LH, Julesz B, Kropfl W.

Electroencephalogr Clin Neurophysiol. 1981 Oct;52(4):298-305.

PMID:
6169506
50.

Visual evoked potentials and the visuogram in multiple sclerosis.

Bodis-Wollner I, Hendley CD, Mylin LH, Thornton J.

Ann Neurol. 1979 Jan;5(1):40-7.

PMID:
426467

Supplemental Content

Support Center